Lymphangitis medical therapy

Jump to navigation Jump to search

Lymphangitis Microchapters

Home

Overview

Historical Perspective

Classification

Causes

Pathophysiology

Differentiating Lymphangitis from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Case Studies

Case #1

Lymphangitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Lymphangitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Lymphangitis medical therapy

CDC on Lymphangitis medical therapy

Lymphangitis medical therapy in the news

Blogs on Lymphangitis medical therapy

Directions to Hospitals Treating Lymphangitis

Risk calculators and risk factors for Lymphangitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]

Overview

Lymphangitis most often is an acute complication following an extension from the skin infection with the potential of a systemic spread. It has to be promptly treated with appropriate antibiotics along with analgesics, anti-inflammatory medications, warm and moist compresses. Certain conditions like nodular lymphagitis that is complicated by abscess and lymphedema with significant lymphatic obstruction may require surgical intervention.

Principles of Therapy

Therapy Based on Clinical Form

Acute Lymphangitis

Empiric Therapy

▸ Click on the following categories to expand treatment regimens.[1]

Acute Lymphangitis

  ▸  Mild - Moderate

  ▸  Severe

Mild - Moderate
Preferred Regimen
Penicillin V 500 mg PO q6h
Alternative Regimen
For Life-Threatening Penicillin Allergies
Clindamycin 300-450 mg PO q8h
OR
Vancomycin 15-20 mg/kg IV q8-12h
For Suspected MSSA
Dicloxacillin 500 mg PO q6h
OR
Cephalexin 500 mg PO q6h
OR
Clindamycin 300-450 mg PO q8h
OR
Erythromycin 500 mg PO q6h
For Suspected MRSA
Vancomycin 15-20 mg/kg IV q8-12h
OR
Linezolid 600 mg IV/PO q12h
OR
Daptomycin 4mg/kg IV q24h
OR
Clindamycin 600 mg IV/PO q8h
OR
Doxycycline 100 mg PO q12h
OR
Minocycline 100 mg PO q12h
OR
TMP-SMX 8-12 mg/kg PO q12h/IV q6h
Severe
Preferred Regimen
Penicillin G 2-4 MU IV q4-6h
Alternative Regimen
For Life-Threatening Penicillin Allergies
Clindamycin 300-450 mg PO q8h
OR
Vancomycin 15-20 mg/kg IV q8-12h
For Suspected MSSA
Dicloxacillin 500 mg PO q6h
OR
Cephalexin 500 mg PO q6h
OR
Clindamycin 300-450 mg PO q8h
OR
Erythromycin 500 mg PO q6h
For Suspected MRSA
Vancomycin 15-20 mg/kg IV q8-12h
OR
Linezolid 600 mg IV/PO q12h
OR
Daptomycin 4mg/kg IV q24h
OR
Clindamycin 600 mg IV/PO q8h
OR
Doxycycline 100 mg PO q12h
OR
Minocycline 100 mg PO q12h
OR
TMP-SMX 8-12 mg/kg PO q12h/IV q6h

References

  1. Moran GJ, Abrahamian FM, Lovecchio F, Talan DA (2013). "Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines". J Emerg Med. 44 (6): e397–412. doi:10.1016/j.jemermed.2012.11.050. PMID 23466022.

Template:WH Template:WS